Introduction
Staging laparotomy with splenectomy was introduced in the early 1970s in the treatment strategies of Hodgkin's disease to determine the extent of the disease. It remains the strongest reliable method for determining abdominal involvement in clinical stages I-II Hodgkin's disease. Several studies have shown that approximately 20%-30% of patients will be upstaged due to pathology findings at laparotomy [4, 8, 20] . Especially involvement of the spleen can hardly be assessed by noninvasive methods such as abdominal computed axial tomography, bipedal lymphangiographie, gallium scanning, or magnetic resonance imaging. In more than 10% of cases there will be a clinically undiagnosed massive involvement of the spleen [7] .
Most treatment strategies have been influenced by the findings of laparotomy. According to the treatment strategies of the GHSG at that time, patients with nonabdominal involvement received radiotherapy alone, whereas upstaged patients were treated by combined modalities or intensive chemotherapy alone.
However, a considerable number of disadvantages have been recognized since institution of obligatory staging laparotomy. The most common problems associated with laparotomy are infection of the wound, bleeding, ileus, embolic disease, septicemia, and pneumonia. Overall these complications can lead to a late onset of therapy or even to death [2, 6, 12, 14, 16, 17, 20] .
In addition, more sophisticated analysis has identified adverse prognostic factors in early-stage HD, justifying a more intensive treatment in these subgroups. The [23] . Thus, the group of patients treated with radiation therapy alone decreased, and subsequently the meaning of staging laparotomy as well [7, 9, 11, 21] . Nevertheless, for patients who could be cured by radiation alone, staging laparotomy remained an important staging procedure until the EORTC published the H6-trial which demonstrated that the survival of patients with and without staging laparotomy is the same although freedom from treatment failure (FFTF) was slightly superior in the laparotomy group [2] . In the present study we evaluate the results of surgical staging in 391 patients in clinical stages I-II without risk factors qualifying for a radiotherapy-based therapy according to the protocol of the (GHSG). A number of factors associated with occult abdominal disease were identified used to identify high-and low-risk subgroups.
Patients and methods
Between February 1988 and January 1993, 1981 previously untreated patients with Hodgkin's disease entered the HD4-6 trials of the GHSG. According to the treatment policy of the GHSG. patients in CS I, II without at least one adverse prognostic factors (large mediastinal mass, extranodal involvement, elevated ESR (>50 mm/hour without and 5=30 mm/hour with B-symptoms) and three or more involved lymph node areas) underwent staging laparotomy and splenectomy. Large mediastinal mass was defined as tumor size 5= onethird of the maximal posterior-anterior thorax diameter. Of these, 391 patients with supradiaphragmatic CS I-II Hodgkin's disease underwent staging laparotomy with splenectomy.
Clinical staging was performed according to the Ann Arbor classification including history, physical examination, blood counts and chemistries, radiography and computer tomography of the chest, ultrasound and computer tomography of the abdomens, scintigraphy of the skeleton, unilateral biopsy of the blood marrow and facultative bipedal lymphangiography. Standard guidelines for surgical staging were used. These included laparotomy by a midline or left upper quadrant incision, splenectomy, excisional biopsy of porta lienalis nodes, of porta hepatic nodes, and from paraaortal, iliacal and mesentenal lymph nodes. Patients with positive lymphangiogramm usually underwent intraoperative radiographic controls to confirm the abnormal nodes.
Selected prognostic factors for occult abdominal disease were evaluated with univariate logistic regression analysis. Using a hierarchical log-linear model we calculated partial associations between the variables of sex, histology, Karnofsky performance status, mediastinal involvement, left cervical involvement and ESR.
To determine the association of the involvement of different supraand infradiphragmatic localizations and areas we estimated the relative risk by calculating the odds ratio (OR) and the approximated 95% confidence interval (95% CI).
P values less than 0.05 were considered to be statistically significant. All tests were performed bi-sided.
Results

Patient characteristics and anatomic distribution
A total of 391 supradiaphragmatic CS I and II patients underwent staging laparotomy and splenectomy and were included in the analysis. Two hundred fifty patients were male (64%) and one hundred forty-one were female (36%). Mean age was 33.8 (±12). TRwenty-eight percent of patients were older than 40 years of age. One hundred ninety-five patients were in CS I (50%), one hundred ninety-six in CS II (50%). Only 6% of patients had B symptoms. The majority of patients had lymphocytepredominant (LP) or nodular sclerosis (NS) histology (64%). Patient characteristics are listed in Table 1 .
There was no deaths due to surgical staging. Laparotomy-associated morbidity was 8%. In 1% we noticed a postoperative ileus, in 3% infection of the wound, in 1% postoperative bleeding, in 0.3% thromboembolic complication. The complications are listed in Table 2 .
Of the 391 patients with supradiaphragmatic CS I, II disease, 82 (21%) had subdiaphragmatic disease detected by laparotomy. The anatomical sites of subdiaphragmatic disease found at laparotomy are listed in (13) 24 (29) 6 (7) 14 (17) 3 (4) Table 3. The spleen was most frequently involved (87%), followed by the splenic hilar nodes (34%), liver hilar nodes (29%), and paraaortic nodes (17%). In 29 patients (35%) the spleen was the only site of subdiaphragmatic disease. In addition, spleen and splenic nodes were exclusively involved in 10 patients (12%). Thus, half of the patients with positive laparotomy findings had occult disease exclusively in the spleen and/or splenic hilar nodes. The liver was involved in 11 patients (13%). Interestingly, in two patients, the liver was found to be the only site ofsubdiaphragmatic disease.
Prognostic factors for subdiaphragmatic disease
Univariate analysis was used to identify those factors in correlation with an increased probability of subdiaphragmatic disease. Sex (P = 0.003), histology (P = 0.004), Karnofsky performance status (P -0.007), mediastinal involvement (P -0.002) and left cervical involvement (P < 0.001) were associated with subdiaphragmatic disease. (96) 17 (22) 65 (21) 20 (27) 62 (20) 30 (25) 52 (19) 41 (32) 41 (16) 16 (19) 66 (22) 32 (26) 50 (19) 7 (23) 75 (21) 9 (28) 73 (20) 15 ( Table 5) .
Estimation of the probability ofsubdiaphragmatic disease
Using the regression coefficients determined in the logistic regression analysis for the four independent predictive factors a mathematical model was derived to provide a quantitative estimate of the probability of subdiaphragmatic disease for individual patients. All tested variants are summarized in Table 6 . The observed and predicted probability for each variant is listed. Correspondence of predicted to observed probability is related to the size of cohort of patients for distinct combination. The correspondence of probabilities is high for combinations with a large cohort and relatively low for combinations with a small cohort of patients. The predicted probability of subdiaphragmatic disease ranged from 6% for patients without left cervical lymph node involvement, with mediastinal involvement, NS/LP histology and Karnofsky index = 10 to 65% for patients with left cervical lymph node involvement, without mediastinal involvement, MC/LD histology and Karnofsky index < 10. The number of patients for distinct combinations ranged from 0.5% (2 patients) to 22% (85 patients) of the entire cohort (391 patients). Only four combinations comprise more than 10% of patients of the cohort as a whole.
To determine high-and low-risk groups, which comprise at least 15% of patients of the cohort and have a risk of subdiaphragmatic involvement of <9% and > 35%, respectively, combinations of only 2 or 3 of the predictive factors were analyzed. With respect to these criteria the following subgroups of patients could be identified as having:
1. low risk for subdiaphragmatic disease (< 9%): a) no left cervical lymph node involvement, mediastinal involvement and Karnofsky index = 10 (n -75, observed risk = 8%); b) no left cervical lymph node involvement, meDiscussion Subdiaphragmatic disease can be precisely diagnosed only by laparotomy. Non-invasive diagnostic procedures are not sufficient for evaluation of abdominal involvement. Envolvement of the spleen in particular can be diagnosed sufficiently only if there is a nodal presentation of disease [3, 10, 15, 19, 20] . With diffuse infiltration of the spleen the sensitivity of non-invasive procedures is less than 50% [15] . But lymphoma involvement of the spleen is typically diffuse and only a small number of patients present with nodal involvement > 1 cm of diameter [18] .
In our series 82 (21%) of 391 patients with CS I, II had subdiaphragmatic involvement. Isolated spleen involvement was found in 29 (35%) of the 82 patients. Eleven of these patients (13%) had no splenic involvement. Analysis by the EORTC of 1059 patients in CS I, II revealed abdominal disease in fewer than 10% if spleen was not involved, but in about 40% of instances of splenic involvement disease was found in other subdiaphragmatic sites [22] .
The advantage of precise diagnosis of the extent of disease must be weighed against the disadvantages. Because of procedure-related morbidity and mortality (10%-15% and l%-3%) staging laparotomy is still under discussion [2, 6, 12, 14, 16, 17, 20] . With the development of more sophisticated chemotherapy regimens the influence of the staging laparotomy on treatment strategies is decreasing.
Several efforts have been made to identify predicting factors for abdominal involvement (Table 7) .
In the analysis of Trotter et al., 24% of 425 patients of early-stage Hodgkin's disease were upstaged to PS III-IV by the laparotomy findings. Spleen involvement was found in 71% of patients with abdominal disease. In this series B-symptoms, histology and gender were correlated with subdiaphragmatic disease. Clinical stage, race and age were not of predictive value [21] . Female patients without systemic symptoms and nodular sclerosis or lymphocyte-predominant histology had the lowest risk of subdiaphragmatic disease (6% and 8%). The highest risk was found in men with B-symptoms and mixed cellularity or lymphocyte-depleted histology (85%, respectively 93%).
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Pendlebury, 1994 [13] No (1 of 24 patients) had the lowest risk for extensive disease [8] . In a study of 915 patients with early-stage Hodgkin's disease, Leibenhaut et al. also described low-and highrisk groups for subdiaphragmatic disease. Female patients in clinical stage I, patients in clinical stage I with mediastinal disease and male patients in clinical stage I with lymphocyte predominant or interfollicular histology had abdominal disease in less than 5%. CS II women who were younger than 27 years and had only two or three sites of disease were also at low risk (9%) [7] .
Comparing the listed studies one can find predictive factors being identified in nearly all studies and others only in single studies. This is partly explainable by biostatistical aspects. The numbers of patients being analyzed range in these studies from 137 up to 1169.
Comparison of the studies is limited by different definitions of patients undergoing laparotomy. Especially in our series, patients in CS I-II with more than two lymph node areas involved, mediastinal mass > onethird of the thoracic diameter, extranodal involvement or high ESR were not laparotomized but treated according to the intermediate-or advanced-stage protocols. Thus, number of lymph node areas or stage were not found to be predictive, probably because only patients with fewer than three lymph node areas involved underwent laparotomy. In our series, only patients with ESR <50 mm/hour without B symptoms and <30 mm/hour in with B symptoms were included. Due to this limitation, ESR was not strongly correlated to subdiaphragmatic disease.
With histology and mediastinal involvement we identified two factors which in other investigations have been shown to be predictive [5, 7] . But Karnofsky Index and left cervical involvement are now described for the first time to be predictive. To our knowledge, Karnofsky performance status was not analyzed in one of the reported series in the literature. We assume that the estimation of this Index was not obligatory or permanently documented. In our series the Karnofsky Index was significant, associated with high ESR (P = 0.01), which was found to be predictive in other series [11] .
The positive correlation of the left cervical lymph nodes and subdiaphragmatic disease emphasizes the importance of the supradiaphragmatic topographical presentation of the disease. The value of the topographical presentation is also shown by the negative correlation of mediastinal involvement and subdiaphragmatic disease found in several studies.
Based on the results of the multivariate analysis we were able to identify high-and low-risk groups for subdiaphragmatic involvement in early-stage Hodgkin's disease. For clinical relevance the risk groups had to fulfill the following requirements: 1. To comprise at least 15% of the analyzed cohort. 2. The expected risk of subdiaphragmatic had to be below 9% in the low-risk group and above 35% in the high-risk group. Fulfilling these criteria the low-risk group comprises patients with no left cervical involvement, mediastinal involvement, and Karnofsky index = 10 (n = 75, observed risk 8%) or nodular sclerosis/lymphocyte predominant histology (n -75, observed risk 8%), and patients with mediastinal involvement, Karnofsky index = 10 and NS/LP histology (n -76, observed risk 8%). High risk for subdiaphragmatic involvement had patients with left cervical lymph node involvement and no mediastinal involvement (« = 98, observed risk 36%) or no mediastinal involvement and MC/LD histology (n = 113, observed risk 40%).
The relevance of predictive factors for subdiaphragnmatic disease depends on the management strategy that is chosen (i.e., with or without laparotomy). In 1982 Bergsagel et al. reported a non-randomized comparison of patients treated at the Princess Margret Hospital from 1968-1977 with patients treated in Stanford during the same time period. Only 21% of patients at the Princess Margret Hospital underwent laparotomy but all patients at Stanford University did so. There was a difference in relapse-free survival in favor of the laparotomized patients but no difference in overall survival [1] .
Only the H6F trial of the EORTC compared in a randomized prospective setting the strategy of laparotomy and treatment according to the findings with the strategy of no laparotomy and subtotal nodal irradiation. At six years, freedom from progression rates were similar in clinical and laparotomy staging (78% vs. 83%, P = 0.27). Survival rates were 93% and 89% (P = 0.24).
Based on the result of the H6F trial it can be concluded that pathology staging is obsolete and identification of risk factors for subdiaphragmatic disease is without clinical or prognostic relevance. But it remains unclear whether the strategies with and without laparotomy are equivalent for all subgroups of patients.
We assume that identification of the high-risk group could be of clinical relevance. The patients belonging to this group could take advantage of early detection of abdominal disease by laparotomy and subsequently of stage-adjusted intensified treatment.
